pharmaphorum

APRIL 23, 2021

The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear noted that the grant comes at a time when many communities are seeing increased demand for behavioural health and recovery services amid the ongoing coronavirus pandemic.

FDA Approval 64

FDA Approval Behavioural Health Clinical Trials Clinical Trials 64

pharmaphorum

OCTOBER 2, 2020

Modia is designed to close the gap as it relates to the access and receipt of quality, evidence-based therapeutic interventions and behavioural health services for individuals with OUD who participate in outpatient treatment with MAT,” said Michael Sumner, Orexo’s chief medical officer.

Behavioural Health 98

Behavioural Health Production FDA Approval Pharma Production 98

pharmaphorum

APRIL 6, 2021

UK digital health company Oxehealth has claimed FDA approval for software that can be used to remotely measure vital signs like heart and breathing rates from a camera feed. . The approval means the Oxford University spin-out can place Oxevision on the market in all US states.

Nurses 59

Nurses Behavioural Health FDA Approval Clinical Trials 59

pharmaphorum

JANUARY 5, 2023

The deal centres on reSET and reSET-O, Pear’s cognitive behavioural therapy (CBT) based programmes, for people living with substance and opioid use disorders, respectively, which have been approved by the FDA as an adjunct to outpatient treatment. Pear secured approval for reSET-O in the following year. “We

Behavioural Health 52

Behavioural Health FDA Approval Licensing Licensing 52